Chris Simon/LinkedIn
Mar 6, 2026, 15:09
Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
Chris Simon, President and Chief Executive Officer at Haemonetics, Member of Board of Directors at Sotera Health Company and AdvaMed, shared on LinkedIn:
”Excited to receive FDA clearance for Persona PLUS, our proprietary, patent‑protected plasma apheresis technology.
This next‑generation, donor‑centric innovation advances the NexSys PCS platform, designed to safely improve yield, speed, and donor satisfaction.
Persona PLUS is supported by data from a randomized clinical trial with 30,000 plus donations from approximately 3,000 donors and was developed with our customers for the benefit of patients worldwide, with a clear focus on IgG yield and lowering cost per gram.”
Stay updated with Hemostasis Today.
-
Jul 27, 2026, 04:50A Significant Step Forward for People with Bleeding Disorders in the Dominican Republic – WFH
-
Jul 27, 2026, 04:11Mohamed F Doheim: Clarifying the Role of Late IV Thrombolysis in the Era of Endovascular Therapy
-
Jul 27, 2026, 03:50Françoise Dignat-George: The Rising Impact of Extracellular Vesicles Spotlighted at ISTH 2026
-
Jul 27, 2026, 03:42Koson Tony Sriamporn: A Milestone for Inclusive Blood Donor Eligibility
-
Jul 27, 2026, 03:34Wolfgang Miesbach: A Standout Talk by Jeffrey Weitz at ISTH 2026
-
Jul 26, 2026, 23:18Mohammadmahdi Sabahi: Proud to Share Our Complete Cushing’s Disease Research Collection
-
Jul 26, 2026, 22:59Mahmood Naseri: The Results of the 2nd Clinical Trial on AriClot Are Now Live in Burns Journal
-
Jul 26, 2026, 16:26Novi Yanti Sari: When MPNs Affect the Heart
-
Jul 26, 2026, 16:21Beyond Drugs: Can Museums Become a Medical Prescription?